(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
A unique overview of all major angiographic lipid intervention trials, presented by their principal investigators. Basic mechanisms and methodological aspects, including biochemical as well as angiographic aspects, are discussed by experts in these fields. A careful comparison of all available data permits an analysis to be made of what may currently be considered proved, which aspects merit further investigation, and which hypotheses should be rejected.
Audience: Clinicians involved in the practice of lipid lowering and investigators involved in lipid-lowering clinical trials. Scientists involved in other areas of lipid research and investigators conducting coronary angiographic trials designed to study the influence of different interventions will find a wealth of information and practical guidelines in this book.
Contents:
One: Mechanisms of progression and regression.- 1. Role of lipoproteins in progression of coronary arteriosclerosis.- 2. Pathophysiological basis for lipid intervention trials.- Two: Methodological aspects of angiographic trials.- 3. The use of metabolic measurements in angiographic regression trials.- 4. Quality control in quantitative coronary arteriography.- 5. Is there a place for visual assessment?.- 6. Angiographic endpoints in progression trials.- Three: Angiographic lipid lowering clinical trials.- 7.The Cholesterol Lowering Atherosclerosis Study (CLAS).- 8. Clinical efficacy and safety of pravastatin treatment in symptomatic patients - the REGRESS trial.- 9. Familial Atherosclerosis Treatment Study.- 10. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC 1): a summary.- 11. The Multicenter Anti-Atheroma Study (MAAS).- 12. Lessons from the Monitored Atherosclerosis Regression Study (MARS) and beyond: atherosclerosis progression/regression responses to therapy depend on lesion size and composition.- 13. The St Thomas' Atherosclerosis Regression Study and an appraisal of its potential limitations.- 14. Effects of the lipid intervention in the Stanford Coronary Risk Intervention Project.- 15. Canadian coronary atherosclerosis study on the effect of lovastatin on the progression of coronary artery disease (CCAIT): why are results different?.- 16. Impact upon angiographic disease progression following step drug therapy in normolipidaemic patients: results of the Harvard Atherosclerosis Reversibility Project (HARP).- 17. Effect of aggressive versus conventional lipid-lowering treatment on coronary and peripheral atherosclerosis: design and baseline characteristics of the LDL-Apheresis Atherosclerosis Regression Study (LAARS).- 18. The NHLBI Post-Coronary Artery Bypass Graft Clinical Trial (Post-CABG): angiographic outcomes.- Epilogue.
PRODUCT DETAILS
Publisher: Springer
Publication date: October, 2011
Pages: 248
Weight: 382g
Availability: Available
Subcategories: Cardiovascular Medicine, Diseases and Disorders
From the same series
